Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021; 23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Bjorg Thorsteinsdottir, MD, Annika Beck, and Jon C. Tilburt, MD, MPH
Good clinicians understand why a patient is asking for a test or treatment, and their skillful counseling can often stem the tide of requests for marginally beneficial tests and procedures.
AMA J Ethics. 2015; 17(11):1028-1034. doi:
10.1001/journalofethics.2015.17.11.ecas2-1511.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Expedited partner therapy is an ethical and effective treatment for sexually transmitted infection, provided patients are reliable messengers to partners.
AMA J Ethics. 2016; 18(3):215-228. doi:
10.1001/journalofethics.2016.18.3.ecas3-1603.
Barry DeCoster, PhD and Lisa Campo-Engelstein, PhD
Expedited partner therapy is an ethical and effective treatment for sexually transmitted infection, provided patients are reliable messengers to partners.
AMA J Ethics. 2016; 18(3):215-228. doi:
10.1001/journalofethics.2016.18.3.ecas3-1603.